<p>Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib</p>

Treatment of polycythemia vera.

BACKGROUND AND OBJECTIVE Current guidelines for the management of patients with polycythemia vera (PV) derive from a few clinical trials and several uncontrolled clinical studies. The purpose of this paper is to critically review the available evidence in literature for selecting the best treatment in the single patient. METHODS The authors have been working in this field contributing origina...

Ruxolitinib for the treatment of patients with polycythemia vera.

Polycythemia vera (PV) is a hematopoietic proliferative disorder associated with Janus-associated kinase/signal transducer and activator of transcription pathway dysregulation resulting in erythrocytosis and, possibly, leukocytosis and thrombocytosis. Patients diagnosed with PV experience a broad range of symptoms associated with a reduced quality of life, often develop splenomegaly, and have a...

Pathogenesis of polycythemia vera.

BACKGROUND AND OBJECTIVE Polycythemia vera (PV) is an acquired clonal myeloproliferative disorder characterized by increased production of mature red cells. We still lack a molecular target responsible for this disorder; however, recent investigations have focused on a number of molecules involved in signal transduction pathways mediated by erythropoietin (Epo) and other growth factors. Here we...

[Therapy of polycythemia vera with myleran].

By NIEL WALD, TAKASHI HOSHINO AND MARY E. SEARS MYLERAN#{176} was developed in the course of a study of the tumor-inhibiting effect of various sulfonic acid esters by Haddow and Timmis.1 Because of the neutropenia, unaccompanied by other side effects, which was observed during its ineffective clinical trial in vaniotis types of cancer in man, Myieran was employed in the treatment of chronic gra...

Muramidase in polycythemia vera.